Unavailable
Unavailable
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/13/2024 | $9.00 | Buy | ROTH MKM |
6/23/2022 | $7.50 | Buy | B. Riley Securities |
12/22/2021 | $7.50 | Buy | Loop Capital |
SUNNYVALE, Calif., Feb. 1, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today the appointment of Robert C. Kill to the company's Board of Directors, effective as of January 30, 2023. Mr. Kill is a skilled healthcare executive with more than 30 years' experience transforming various healthcare-related companies. In his most recent executive position as CEO of Parata Systems, Mr. Kill grew company revenue over 5X during his tenure before it sold last year for more than $1.5 billion. Before Parata, Mr. Kill was affiliated with two private equity funds, Frazie
LYON, France, December 6, 2022 -- EDAP TMS SA (NASDAQ:EDAP) (the "Company"), the global leader in robotic energy-based therapies, announced today that the Company has hired medical capital equipment finance industry veteran Ken Mobeck as Chief Financial Officer of EDAP Technomed Inc., the Company's U.S. subsidiary. During his extensive career, Mr. Mobeck has demonstrated significant leadership expertise in driving transformational business growth while establishing a track record of creating lasting shareholder value. Marc Oczachowski, Chairman and Chief Executive Officer of EDAP TMS, stated, "I am very pleased to welcome Ken onboard our U.S. subsidiary. Ken is a great addition to Ryan Rh
SUNNYVALE, Calif., June 15, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Franco N. Palomba has joined the company as vice president, chief accounting officer & controller. Mr. Palomba will be responsible for the controllership function, including the global accounting organization and associated budgetary and administrative operations, as well as financial and regulatory compliance. He will report to Accuray senior vice president & chief financial officer Ali Pervaiz. Mr. Palomba is a skilled executive with more than 30 years of accounting and f
Accuray is the first industry partner to open a facility at the Genolier Innovation Hub, created to provide opportunities for clinician-industry collaborations that can help accelerate improvements in patient careNew Accuray CyberComm™ tool was used to significantly reduce the CyberKnife® S7™ System's commissioning time and enable product training in Genolier to begin more quicklyMADISON, Wis., Sept. 30, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today the initiation of CyberKnife® S7™ System medical professional training at its education center located within the newly opened Genolier Innovation Hub, a fully-owned subsidiary of AEVIS VICTORIA SA, in Switzerland. As th
The Technology Will Play an Important Role in the Hospital's Plan to Expand Patient Access to High Precision Radiation Therapy Treatments MADISON, Wis., Sept. 10, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Gifu Prefectural General Medical Center is setting a new standard in cancer care in Japan as the first hospital in the country to treat patients with surface-guided radiation therapy (SGRT) using the company's Radixact® Radiation Delivery System and VitalHold™* package. SGRT is designed to help medical care teams to effectively position the patient and confidently monitor the accuracy of that positioning throughout treatment. The ability to confidently mon
MADISON, Wis., Sept. 3, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that President and Chief Executive Officer Suzanne Winter will be taking a temporary medical leave of absence to receive care for a treatable form of cancer, effective immediately. Accuray Senior Vice President and Chief Commercial Officer Sandeep Chalke will serve as the interim CEO during Ms. Winter's absence. To ensure that Mr. Chalke and the organization have the necessary support, the company has formed an Executive Committee of the Board of Directors, consisting of Joseph Whitters, Chairman of the Accuray Board, and Anne Le Grand, Chair of the Science and Technology Committee, that will advi
SC 13G/A - ACCURAY INC (0001138723) (Subject)
SC 13G - ACCURAY INC (0001138723) (Subject)
SC 13G/A - ACCURAY INC (0001138723) (Subject)
Under the terms of the agreement, TrueNorth Medical Physics will offer services that are complementary and supplementary to those supplied by Accuray, acting as an extension of the hospital team – on-site, remote or hybrid
Accuray Incorporated (NASDAQ:ARAY) announced today that the registration dossier for the Accuray Precision® Treatment Planning System (TPS) has been approved by the Chinese National Medical Products Administration (NMPA). The Accuray Precision TPS is now available for use with the CNNC-Accuray joint venture Tomo® C radiation therapy system and in combination, will provide medical care teams with a new option for delivering extremely precise and accurate radiotherapy treatments, ultimately expanding access to care for more cancer patients in China.
4 - ACCURAY INC (0001138723) (Issuer)
DEFA14A - ACCURAY INC (0001138723) (Filer)
DEF 14A - ACCURAY INC (0001138723) (Filer)
10-K - ACCURAY INC (0001138723) (Filer)
ROTH MKM initiated coverage of Accuray with a rating of Buy and set a new price target of $9.00
B. Riley Securities initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50
Loop Capital initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50
14% Revenue and 8% Orders Growth in Q4; Company issues FY25 Guidance MADISON, Wis., Aug. 14, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the fourth quarter and fiscal 2024, ended June 30, 2024. Fourth Quarter Fiscal 2024 Summary Net revenue of $134.3 million, an increase of 13.5 percent from the same period in the prior fiscal year. Net revenue on a constant currency basis was $136.7 million, which represents a 15.6 percent increase versus the same period in the prior fiscal year.GAAP net income of $3.4 million, as compared to G
MADISON, Wis., July 31, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the fourth quarter of fiscal year 2024, ended June 30, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on August 14, 2024. The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (internationa
MADISON, Wis., May 1, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the third quarter and nine-months ended March 31, 2024. Third Quarter Fiscal 2024 Summary Net revenue of $101.1 million decreased 14 percent from the same period in the prior fiscal year. Net revenue on a constant currency basis was $102.4 million, which represented a 13 percent decrease from the same period in the prior fiscal year.GAAP net loss was $6.3 million, as compared to GAAP net income of $0.6 million in the same period in the prior fiscal year. Adjusted
4 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)